Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICL670 extension study in sickle cell disease with transfusional iron overload
2004-000597-31Phase 2Completed
- Sponsor
- Novartis
- Start
- Feb 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of deferasirox in transfusional hemosiderosis and sickle cell disease (SCD), sponsored by Novartis. Primary endpoint: Long-term safety and tolerability of ICL670. Started Feb 2005; status: completed.
02
Drugs
deferasirox
03
Conditions
transfusional hemosiderosissickle cell disease (SCD)
Beyond the preview
Go deeper on 2004-000597-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000597-31.